Barclays
TBPH icon

Barclays’s Theravance Biopharma TBPH Stock Holding History

Barclays’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-112
Closed -$2K – 7254
2014
Q4 		$2K Hold
112
– – ﹤0.01% 7122
2014
Q3 		$3K Sell
112
-112
-50% -$3.25K ﹤0.01% 7330
2014
Q2 		$7K Buy
+224
New +$6.74K ﹤0.01% 7004

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Barclays's TBPH Position: Q2 2026 in Review

Barclays reduced its Theravance Biopharma (TBPH) stake by 8.3% in Q2 2026, selling an estimated $63.8K and leaving 42,525 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #2984.

Barclays first reported a position in TBPH in Q2 2014 and has held it in 49 quarters since. The position peaked at $2.09M in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Barclays held 42,525 shares of Theravance Biopharma worth $723K as of Q2 2026.
  • Barclays sold 3,851 Theravance Biopharma shares in Q2 2026, an estimated $63.8K.
  • Theravance Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2984 holding.
  • Barclays first reported a position in Theravance Biopharma in Q2 2014 and has held it in 49 quarters since.
  • Barclays's Theravance Biopharma position peaked at $2.09M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.